Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expressing Solid Tumors”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Early research (Phase 1)Active Not RecruitingNCT05311397
What this trial is testing

A166 in Patients With Advanced Solid Malignant Tumors

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 120
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Testing effectiveness (Phase 2)Looking for participantsNCT07512583
What this trial is testing

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 178
Not applicableEnded earlyNCT02840110
What this trial is testing

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Who this might be right for
B Cell LymphomasMultiple MyelomaSolid Tumor+1 more
Cogent Biosciences, Inc. 22
Early research (Phase 1)UnknownNCT06154343
What this trial is testing

GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd. 150
Early research (Phase 1)UnknownNCT06254807
What this trial is testing

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positive
Carisma Therapeutics Inc 6
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Testing effectiveness (Phase 2)UnknownNCT05349409
What this trial is testing

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Who this might be right for
Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 212
Early research (Phase 1)Not Yet RecruitingNCT07036185
What this trial is testing

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Who this might be right for
Gastric/Gastroesophageal Junction CancerBreast CancerColorectal Cancer+3 more
Shanghai Bao Pharmaceuticals Co., Ltd. 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT06271837
What this trial is testing

T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Who this might be right for
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca 127
Testing effectiveness (Phase 2)Looking for participantsNCT07617805
What this trial is testing

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Who this might be right for
Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech 42
Early research (Phase 1)Study completedNCT00095537
What this trial is testing

BMS-599626 in Patients With Advanced Solid Malignancies

Who this might be right for
CancerMetastases
Bristol-Myers Squibb 60
Testing effectiveness (Phase 2)Looking for participantsNCT06695845
What this trial is testing

Zanidatamab in Patients With HER2-expressing Tumors

Who this might be right for
Breast CancerGastric CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals 200
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Not applicableActive Not RecruitingNCT07387874
What this trial is testing

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Who this might be right for
Recurrent or Metastatic Solid Tumors
Lixiaoling 30
Early research (Phase 1)Study completedNCT04257110
What this trial is testing

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Who this might be right for
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd 117
Load More Results